Welcome to our dedicated page for CME GROUP SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CME GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CME GROUP's regulatory disclosures and financial reporting.
CME Group Inc. director Dennis Suskind reported selling 748 shares of Class A common stock on February 6, 2026 at a price of $300 per share. After this transaction, he beneficially owned 2,699 shares of CME Group common stock in direct ownership.
CME Group has a holder filing a notice under Rule 144 to sell up to 748 shares of Class A common stock through J.P. Morgan Securities on the NASDAQ around 02/06/2026. Shares outstanding were 360,596,647, indicating this is a very small potential sale relative to the total.
CME Group Inc. filed a current report to furnish its earnings press release for the quarter and year ended December 31, 2025. The press release, dated February 4, 2026, is attached as Exhibit 99.1 and outlines the company’s financial results.
The release includes several non-GAAP financial measures, such as adjusted revenues, expenses, operating income, net income and earnings per share. Management states these are intended to supplement GAAP results and improve comparability with prior periods, and provides reconciliations to the most directly comparable GAAP figures in accordance with Regulation G.
CME Group Inc. filed an 8-K to note that on February 2, 2026 it communicated pricing changes to its clients through Special Executive Report 9676. The company states that a copy of this pricing notice has been posted to its website.
The disclosure is furnished under Item 7.01, meaning it is treated as information provided for Regulation FD purposes. CME Group clarifies that this information is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated into other securities law filings unless specifically referenced.
CME Group Inc. reported that its Chairman and CEO Terrence A. Duffy, who is also a director, sold 25,000 shares of Class A common stock on December 11, 2025.
The sale was executed in two trades: 13,809 shares at prices ranging from $268.66 to $269.66 per share and 11,911 shares at prices ranging from $269.68 to $270.51 per share, with prices within each $1 range aggregated and reported on a weighted-average basis. After these transactions, Duffy directly beneficially owned 65,804 Class A shares.
CME Group Inc. officer Derek Louis Sammann, Senior Managing Director and Global Head of Commodities Markets, reported several transactions in CME Class A common stock. On November 6, 2025, he transferred 2,300 shares at a stated price of $0, reducing his direct holdings to 8,683 shares and increasing the holdings of his revocable living trust to 16,914 shares, reflecting an internal ownership reorganization.
On November 20, 2025, the trust sold 5,886 shares at $275.65 per share, leaving the trust with 11,028 shares. On the same date, Sammann’s spouse sold 1,314 shares at $275.74 per share, leaving 7,022 shares held by the spouse. These trades update disclosed indirect ownership positions through both the trust and spouse.
CME Group (CME) insider transaction: Officer Hilda Harris Piell, Sr MD & Chief HR Officer, reported a Code G gift of 973 Class A common shares on 11/07/2025 at a reported price of $0. Following the transaction, she beneficially owns 29,418 shares, held directly.
The filing notes the shares were gifted to her donor advised fund. This is a charitable transfer rather than a market sale.
CME Group Inc. (CME) reported an insider transaction: Director Harold Ford Jr. sold 1,000 Class A shares on November 3, 2025, coded S (open market sale). The weighted average sale price was $263.53, with a price range of $263.21–$263.68.
Following the sale, he directly owns 1,091 shares. The company notes prices within a $1 range were aggregated and maintains detailed records available upon request.
CME Group Inc. reported Q3 2025 results with total revenue of $1,537.6 million versus $1,584.4 million a year ago as lower futures and options activity reduced clearing and transaction fees. Operating income was $972.6 million with a 63.3% operating margin. Net income was $908.0 million, and diluted EPS was $2.49.
Market data and information services grew to $202.5 million (up 14% year over year), partly offsetting softer trading revenues. Non‑operating income of $204.4 million reflected high investment income driven by reinvestment of performance bond collateral, net of distributions to clearing members.
Year‑to‑date, operating cash flow reached $3,143.2 million. The company paid dividends of $1.25 per share in Q3 (total $3.75 per share YTD) and repurchased 32,265 shares for $8.2 million. CME refinanced debt—retiring $750.0 million due 2025 and adding $750.0 million due 2030—bringing long‑term debt to $3,421.3 million. Subsequent event: on October 10, 2025, CME and S&P Global completed the sale of OSTTRA (EV $3.1 billion split 50/50); CME expects to recognize a ~$300.0 million gain in Q4 2025.